GUTS

Fractyl Health, Inc. operates as a metabolic therapeutics company focused on developing organ-based treatments for metabolic diseases, including type 2 diabetes and obesity. Headquartered in Lexington, Massachusetts, the company pioneered Rejuva, a minimally invasive endoscopic procedure that uses hydrothermal energy to ablate the duodenal mucosa, targeting the root cause of metabolic dysfunction in the small intestine. The therapy aims to improve glycemic control and metabolic health by resurfacing the intestinal lining, potentially offering disease modification rather than symptom management. Fractyl's clinical development program includes multiple trials evaluating Rejuva's safety and efficacy, with data demonstrating meaningful improvements in HbA1c levels and metabolic markers in patients with type 2 diabetes. The company operates in the emerging field of gut-based metabolic interventions, positioning itself as an alternative to pharmacological treatments and bariatric surgery. In March 2024, Fractyl completed its merger with special purpose acquisition company Panacea Acquisition Corp. II, becoming publicly traded under the ticker symbol GUTS on the Nasdaq exchange. The transaction provided capital to advance clinical programs and support regulatory pathways toward commercialization. With a focus on addressing the growing global burden of metabolic disease, Fractyl represents a novel approach combining gastroenterology and endocrinology through its proprietary duodenal mucosal resurfacing technology.